Risk Assessment in Stage II Colon Cancer
In this supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer from different angles.
Risk Assessment in Stage II Colon Cancer
This supplement and associated publication costs were funded by Genomic Health.
Over the past years, our understanding of stage II colon cancer has made significant advances leading to a refinement in the identification of the patient population and the treatment options considered appropriate as adjuvant therapy in this setting. In this supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
